Case report: Germline BRCA 2 mutation in primary peritoneal carcinoma: a rare malignancy

Yan-Ying Huang; Yue Zhang; Wen-Jun Xie; Zhao-Dong Li

doi:10.3389/fonc.2024.1428918

Frontiers in Oncology (Sep 2024)

Case report: Germline BRCA 2 mutation in primary peritoneal carcinoma: a rare malignancy

Yan-Ying Huang,
Yue Zhang,
Wen-Jun Xie,
Zhao-Dong Li

Affiliations

Yan-Ying Huang: Department of Pathology, Hangzhou Red Cross Hospital, Hangzhou, China
Yue Zhang: Department of Radiology, Hangzhou Red-Cross Hospital, Hangzhou, China
Wen-Jun Xie: Department of Pathology, Zhejiang Hospital of Traditional Chinese Medicine, Hangzhou, China
Zhao-Dong Li: Department of Clinical laboratory, Hangzhou Red Cross Hospital, Hangzhou, China

DOI: https://doi.org/10.3389/fonc.2024.1428918
Journal volume & issue: Vol. 14

Abstract

Read online

BackgroundPrimary peritoneal carcinoma (PPC) is a rare malignancy. Clinically, its histological morphology resembles that of epithelial ovarian tumors (EOC), often leading to misdiagnosis. Diagnosis and treatment of PPC are time-sensitive because of the rapidly progressive nature of the disease.Case reportHerein, we report the case of a 54-year-old woman who was initially diagnosed with ovarian cancer; however, extensive workup showed evidence of Müllerian PPC origin. Furthermore, the patient harbored a targetable BRCA mutation.ConclusionThe patient was treated with the BRCA-targeting agents and had a good prognosis after surgery.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords